Open AccessPlatelet biomarkers identifying mild cognitive impairment in type 2 diabetes patients
Author(s) -
Yu Haitao,
Liu Yanchao,
He Ting,
Zhang Yao,
He Jiahua,
Li Mengzhu,
Jiang Bijun,
Gao Yang,
Chen Chongyang,
Ke Dan,
Liu Jianjun,
He Benrong,
Yang Xifei,
Wang JianZhi
Publication year - 2021
Publication title -
aging cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.103
H-Index - 140
eISSN - 1474-9726
pISSN - 1474-9718
DOI - 10.1111/acel.13469
Subject(s) - optineurin , diabetes mellitus , mitophagy , medicine , biology , type 2 diabetes mellitus , cognitive decline , type 2 diabetes , autophagy , bioinformatics , endocrinology , disease , biochemistry , dementia , amyotrophic lateral sclerosis , apoptosis
Type 2 diabetes mellitus (T2DM) is an independent risk factor of Alzheimer's disease (AD). Therefore, identifying periphery biomarkers correlated with mild cognitive impairment (MCI) is of importance for early diagnosis of AD. Here, we performed platelet proteomics in T2DM patients with MCI (T2DM‐MCI) and without MCI (T2DM‐nMCI). Pearson analysis of the omics data with MMSE (mini‐mental state examination), Aβ1‐42/Aβ1‐40 (β‐amyloid), and rGSK‐3β(T/S9) (total to Serine‐9‐phosphorylated glycogen synthase kinase‐3β) revealed that mitophagy/autophagy‐, insulin signaling‐, and glycolysis/gluconeogenesis pathways‐related proteins were most significantly involved. Among them, only the increase of optineurin, an autophagy‐related protein, was simultaneously correlated with the reduced MMSE score, and the increased Aβ1‐42/Aβ1‐40 and rGSK‐3β(T/S9), and the optineurin alone could discriminate T2DM‐MCI from T2DM‐nMCI. Combination of the elevated platelet optineurin and rGSK‐3β(T/S9) enhanced the MCI‐discriminating efficiency with AUC of 0.927, specificity of 86.7%, sensitivity of 85.3%, and accuracy of 0.859, which is promising for predicting cognitive decline in T2DM patients.